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ABSTRACT 1 
In this work, the optimization of an effective protocol for cell metabolomics is described with especial 2 
emphasis in the sample preparation and subsequent analysis of intracellular metabolites from adherent 3 
mammalian cells by capillary electrophoresis-mass spectrometry. As case study, colon cancer HT-29 4 
cells, a human cell model to investigate colon cancer, are employed. The feasibility of the whole method 5 
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for cell metabolomics is demonstrated via a fast and sensitive profiling of the intracellular metabolites of 6 
HT-29 cells by capillary electrophoresis-time-of-flight mass spectrometry (CE-TOF MS). The suitability 7 
of this methodology is further corroborated through the examination of the metabolic changes in the 8 
polyamines pathway produced in colon cancer HT-29 cells by difluoromethylornithine (DFMO), a known 9 
potent ornithine decarboxylase inhibitor. The selection of the optimum extraction conditions allowed a 10 
higher sample volume injection that led to an increase in CE-TOF MS sensitivity. Following a non-11 
targeted metabolomics approach, 10 metabolites (namely, putrescine, ornithine, gamma-aminobutyric 12 
acid (GABA), oxidized and reduced glutathione, 5’-deoxy-5’-(methylthio)adenosine, N-acetylputrescine, 13 
cysteinyl-glycine, spermidine and an unknown compound) were found to be significantly altered by 14 
DFMO (p<0.05) in HT-29 cells. In addition to the effect of DFMO on polyamine metabolism, minor 15 
modifications of other metabolic pathways (e.g., related to intracellular thiol redox state) were observed. 16 
 17 
Keywords: Metabolomics, capillary electrophoresis-mass spectrometry, human colon adenocarcinoma 18 
HT-29 cells, adherent mammalian cells, polyamines, difluoromethylornithine 19 
Abbreviations: 20 
CHO, chinese hamster ovary; PBS, phosphate-buffered saline; CE-TOF MS, capillary electrophoresis-21 
time-of-flight mass spectrometry; DFMO, difluoromethylornithine; GABA, -aminoisobutyric acid; 22 
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMSO, dimethyl sulfoxide; QC, 23 
quality control; W, water; AW, acidified water; IAW, isopropyl alcohol-acetonitrile-water; PCA, 24 
principal component analysis; EIE, extracted ion electropherogram; ODC, ornithine decarboxylase; MTA, 25 
5’-deoxy-5’-(methylthio)adenosine; SAM, S-adenosylmethionine; SAH, S-adenosyl-L-homocysteine; 26 
GSH, reduced glutathione; GSSG, oxidized glutathione.  27 
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1. INTRODUCTION 28 
Metabolomics is a valuable tool for investigating cellular responses and to explore the underlying 29 
mechanisms of external actions on metabolic pathways. Cell culture metabolomics represents a major 30 
opportunity in many different areas (including e.g., discovery of drug targets [1], biotechnology [2], 31 
phenotype markers [3], biopharmaceutical production [4], metabolic flux analysis [5,6], foodomics [7,8], 32 
among others), however, the application of metabolomics in the area of cell cultures is somewhat 33 
undeveloped. Although not specific to cell metabolomics, the broad physico-chemical diversity of 34 
metabolites as well as the broad dynamic range of their concentration, are main challenges in 35 
metabolomics. Extraction of metabolites from any given biological sample is one of the most important 36 
steps for the generation of meaningful results. A suitable metabolite extraction protocol should remove 37 
interfering media components, and quantitatively extract as many metabolites as possible without causing 38 
chemical or physical degradation. Moreover, it is assumed that the subset of observed metabolites will 39 
depend on both sample processing and analytical platform used to analyze them [9-10]. The development 40 
of robust and standardized sampling procedures for intracellular metabolite analysis from cell cultures 41 
represents today an important challenge [11]. Among others, the type of cellular organism under study 42 
affects the overall sample preparation process, because the leakage of metabolites during sample 43 
processing is likely to be dependent on cell wall and membrane structure. Until now, different extraction 44 
methods have been presented for intracellular metabolic profiling of different microorganisms [12,13], 45 
including yeast and bacteria [14]. Several approaches have been reported for the extraction of intracellular 46 
metabolites from mammalian cells growing in suspension, such as Chinese hamster ovary (CHO). In this 47 
latter case, special attention has been given to the interest of CHO for producing recombinant proteins 48 
[15-20]. The growing mode (adherent or non-adherent) of the different mammalian cells will also be 49 
critical for the sample preparation step prior to metabolomics, especially in the first stages of the sample 50 
preparation process. In cell cultures all the components of culture media comprise a significant potential 51 
source of variability, and thus, to reduce variance in metabolic profile/fingerprint the use of the same 52 
4 
 
growth medium is recommended for all cell cultures of a certain experiment. In any case, the growth 53 
medium is certainly a source of contamination for intracellular metabolomics, and thus, cells must be 54 
efficiently washed to avoid contamination with exogenous compounds. Therefore, general sample 55 
preparation of intracellular cell metabolomics comprises two steps; the first one provides washed and 56 
quenched cells while in the second step intracellular metabolites are extracted. 57 
Metabolic content must also be representative of the metabolic state of the cell culture, however, the 58 
effectiveness of the different methods described in literature for metabolism quenching is still under 59 
discussion and in certain cases it is even possible to see contradictory results regarding their adequacy and 60 
performance. Temperature shock maintaining the cells below -20 ºC has been widely used for metabolic 61 
quenching [21,22]. When applying quenching procedures using cold solvents the time lap between 62 
sampling and the inhibition of metabolism is minimal, however, contact with organic solvents may 63 
produce cell wall/membrane permeabilization. Indeed, drastic loss of intracellular metabolites during the 64 
quenching step has been reported for cold solvents such as methanol when used prior to intracellular 65 
metabolite extraction in bacteria [12,13], and in CHO mammalian cells grown in suspension [17]. On the 66 
other hand, the use of washing/quenching solutions with too low ionic strength might result in a 67 
significant metabolite leakage, so this approach should also be handled with care. Reducing temperature, 68 
enzymatic reaction velocity will strongly decrease, and with that, the unwanted metabolites changes will 69 
be reduced. The use of cold isotonic PBS to remove residues surrounding the cells (culture medium, for 70 
example) minimizes the conversion of metabolites with a rapid turnover [17-19]. Some recent works have 71 
claimed the benefits of combining in a single step quenching and extraction procedures in mammalian 72 
adherent cells [23,24], although the latter procedures skip any reliable normalization strategy. The 73 
importance of normalization is too often underestimated in cell culture metabolomics, and it is 74 
particularly critical when the cells are exposed to certain conditions that induce or inhibit cell 75 
proliferation [25]. 76 
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Capillary electrophoresis-mass spectrometry (CE-MS) is a thoughtful methodology to analyze polar ionic 77 
compounds, and is becoming more and more routine in metabolomics field [26-31]. In this work, we 78 
describe in detail an effective sample preparation procedure for intracellular metabolite extraction in a 79 
model of adherent mammalian cells, namely, human colon cancer HT-29 cells. The feasibility of the 80 
proposed sample treatment prior to metabolomics of the intracellular content of adherent HT-29 cells was 81 
demonstrated through the examination via capillary electrophoresis-time-of-flight mass spectrometry 82 
(CE-TOF MS) of the metabolic changes produced by difluoromethylornithine (DFMO), an ornithine 83 
decarboxylase inhibitor with reported anti-proliferative activity against several cancer cell lines. 84 
 85 
2. MATERIALS AND METHODS 86 
2.1. Chemicals 87 
Ammonium acetate, sodium hydroxide, sodium chloride, methanol, dimethyl sulfoxide (DMSO) and 88 
isopropyl alcohol were from Sigma-Aldrich (St. Louis, MO, USA) and purchased with the highest purity 89 
available. MS grade formic acid and isopropyl alcohol were from Riedel-de Haën (Seelze, Germany) and 90 
acetonitrile was from Labscan (Gliwice, Poland). Deionized water was obtained by using a Milli-Q 91 
system from Millipore (Bedford, MA, USA). The following commercial standards were from Sigma-92 
Aldrich: glutathione, glutathione oxidized, spermine, spermidine, putrescine, cadaverine, N-93 
acetylspermine, ornithine, lysine, arginine, S-adenosylmethionine, adenine, N-acetylputrescine, S-94 
adenosylhomocysteine, cysteine, cytidine, methionine, adenosine, 5’-deoxy-5’-(methylthio)adenosine, -95 
aminoisobutyric acid (GABA), tyramine and methionine sulfone. 96 
 97 
2.2. Cell culture and DFMO treatment 98 
Colon adenocarcinoma HT-29 cell line obtained from ATCC (American Type Culture Collection, LGC 99 
Promochem, UK) was grown in McCoy’s 5A (from Lonza, Barcelona, Spain) supplemented with 10% 100 
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heat-inactivated fetal calf serum (from Biowest, Nuaillé, France), 50 U/mL penicillin G and 50 U/mL 101 
streptomycin (Lonza), at 37 ºC in humidified atmosphere with 5% CO2. When cells reached ~50% 102 
confluence, they were trypsinized, neutralized with culture medium, plated in different culture plates and 103 
allowed to adhere overnight at 37 ºC. To study the effect of DFMO on proliferation of HT-29 line, cells 104 
were seeded onto 96-well culture plates at 10,000 cells/cm
2
, permitted to adhere overnight at 37 ºC, and 105 
exposed to 4.6 mM DFMO for 0-72 h. After incubation, cell proliferation was estimated by the MTT 106 
assay as follows: 0.5 mg/mL of MTT reagent (Sigma-Aldrich) was added and incubated for 3 h at 37 ºC 107 
in humidified atmosphere with 5% CO2. After incubation, the media was aspirated and 100 µL of DMSO 108 
was added to each well to dissolve the formazan (the metabolic product from MTT). Then, the absorbance 109 
at 570 nm was measured in a microplate reader Multiskan™ FC Microplate Photometer from Thermo 110 
Fisher Scientific (Vantaa, Finland). Results are provided as the mean ± SEM (standard error of the mean) 111 
of five replicates. The results were analyzed by the analysis of variance (ANOVA) with Tukey post hoc 112 
test and differences were considered significant at p<0.05. To evaluate different protocols for metabolite 113 
extraction, 10,000 cells/cm
2
 were seeded onto P150 tissue culture dishes, permitted to adhere overnight at 114 
37 ºC, and incubated with culture medium for a given time. Cells from different plates were pooled, and 115 
after counting, ten million cells were subjected to intracellular metabolite extraction with four different 116 
extraction solvents (five replicates each). To study the effect of DFMO on HT-29 line using a 117 
metabolomic approach, P150 tissue culture dishes were seeded with 10,000 cells/cm
2
, permitted to adhere 118 
overnight at 37 ºC, and incubated with 4.6 mM of DFMO in complete culture medium for 48 h. Three 119 
independent experiments were performed to compare metabolic profiles from DFMO-treated and non-120 
treated cells. After incubation, cells were subjected to intracellular metabolite extraction as described 121 
below. 122 
 123 
2.3. Intracellular metabolite extraction 124 
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After incubation, growth medium from culture plates was removed by aspiration, and cells were 125 
trypsinized and pelleted [31]. Cells were then washed with 1 mL of cold PBS and counted in a Neubauer 126 
counting chamber using a light microscope (ID3, Carl Zeiss, Jena, Germany). After counting, 10 × 10
6
 127 
cells were subjected to metabolite extraction. 300 µL cold extraction solvent spiked with internal 128 
standards (tyramine and methionine sulfone at 125 µM) and 300 mg abrasive 212-300 µm beads glass 129 
balls (Sigma-Aldrich) were added to and immediately frozen in liquid nitrogen for 3 min. Thawing was 130 
carried out in a ultrasonic bath at 50 Hz (Ultrasons from JP Selecta, Barcelona, Spain). Then, cells were 131 
disrupted using a mixer mill MM 400 from Retsch GmbH (Haan, Germany) at a frequency of 30 Hz for 3 132 
min. Three cycles of freezing/thawing and mechanical disruption were performed. Cell debris was 133 
separated from intracellular metabolic content by centrifugation at 24,000xg for 10 min at 4ºC. When 134 
aqueous solutions were used for extractions, 200 µL of the supernatant were ultrafiltrated by using 3 kDa 135 
Amicon Ultra 0.5 mL centrifugal devices from Millipore (Billerica, MA, USA) at 14,000xg for 40 min at 136 
20 °C and then stored at -80 °C until CE-MS analysis. Supernatants obtained with organic solvents were 137 
directly stored at -80 °C until CE-MS analysis.  138 
 139 
2.4. Metabolite analysis by CE-MS 140 
Metabolic profiling was carried out using a P/ACE 5500 capillary electrophoresis (CE) system (Beckman 141 
Instruments, Fullerton, CA, USA) connected to a time-of-flight mass spectrometer (TOF MS) instrument 142 
(micrOTOF model) from Bruker Daltonics (Bremen, Germany) using an orthogonal electrospray 143 
ionization (ESI) interface G1607A from Agilent Technologies (Palo Alto, CA, USA). Metabolites were 144 
separated in a fused silica capillary (80 cm, 50 μm i.d., 375 μm o.d.) filled with 3 M formic acid as 145 
background electrolyte (BGE) applying a voltage of +27 kV at 25ºC. Before first use, the fused-silica 146 
separation capillary was conditioned by rinsing with 1 M NaOH for 10 min, followed by 20 min with 147 
Milli-Q water. Before each CE-MS analysis the capillary was conditioned with the separation buffer 148 
during 4 min. Sample injections were made at the anodic end using N2 pressure of 0.5 psi for 16 s (12 nL) 149 
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or 32 s (24 nL). Isopropyl alcohol-water (1:1, v/v) was delivered as the sheath liquid at 0.24 µL/min by a 150 
74900-00-05 Cole Palmer syringe pump (Vernon Hills, IL, USA). ESI-TOF MS was performed in the 151 
positive ion mode, and the capillary voltage was set at 4 kV. The flow rate of heated dry nitrogen gas 152 
(heater temperature, 200 °C) was maintained at 0.4 bar. External and internal calibration of the TOF-MS 153 
instrument was performed by introducing a 10 mM sodium formate solution through the separation 154 
capillary. The ions used for the calibration of the TOF-MS instrument were 90.9766, 158.9641, 226.9515, 155 
294.9389, 362.9263, 430.9138, 498.9012 and 566.8886 m/z. Each sample was analyzed in duplicate by 156 
CE-MS 157 
 158 
2.5. Data analysis 159 
Metabolomic data signals obtained from CE-TOF MS were exported to the MS exchange format 160 
*.mzXML using MSConvert tool from Proteowizard program (available at 161 
http://proteowizard.sourceforge.net/downloads.shtml). CE-MS data was then processed with MZmine 162 
program (version 2.7.2) [33]. Parameters applied for mass detection, peak deconvolution and sample 163 
alignment are described elsewhere [7]. Peaks showing high variability (with a value of median/average > 164 
1.5) and peaks not found in at least 80% of samples within the same data set (i.e. same culture conditions 165 
and extraction solvent) were removed from the subsequent data processing steps. The resulting output 166 
*.csv data tables of high quality time-aligned detected peaks with their corresponding migration time, m/z 167 
and peak area obtained for each sample were merged into one file to perform statistical analysis using 168 
STATISTICA program (v.7, Statsoft, Tulsa, OK, USA, www.statsoft.com). In order to compare and to 169 
evaluate the different metabolite coverage from the four extraction protocols a principal component 170 
analysis (PCA) was performed. An analysis of variance (ANOVA) with p-value set at 0.05 was applied to 171 
determine the differences between control and DFMO treated HT-29 cells after the application of the 172 
optimum metabolite extraction protocol. Metabolites showing significant differences (p<0.05) after 173 
DFMO treatment were subjected to tentative identification process by matching the experimental accurate 174 
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m/z values and those contained in different free available databases, namely, Human Metabolome 175 
Database [34], METLIN [35], and KEGG [36], with a mass accuracy window of 10 ppm. When available, 176 
commercial standards were co-injected to support tentative metabolite identifications. 177 
 178 
3. RESULTS AND DISCUSSION 179 
 180 
3.1. CE-TOF-MS analysis 181 
As mentioned above, metabolites were separated in a fused silica capillary (80 cm, 50 μm i.d.) filled with 182 
3 M formic acid as background electrolyte applying a voltage of +27 kV at 25ºC. For the metabolomic 183 
study, a quality control (QCs) mixture containing 19 metabolite standards (spermine, spermidine, 184 
putrescine, cadaverine, N-acetylspermine, ornithine, lysine, arginine, S-adenosylmethionine, adenine, N-185 
acetylputrescine, S-adenosyl-L-homocysteine, N-acetylornithine, cytidine, methionine, adenosine, 5’-186 
deoxy-5’-(methylthio)adenosine, oxidized glutathione and reduced glutathione) at 0.1 mM each, was used 187 
to monitor the reliability and repeatability of the results. An example of the separations obtained is shown 188 
in Fig. 1. As can be seen, under these conditions an efficient and fast separation of the 19 metabolites 189 
could be obtained in less than 12 minutes by CE-TOF-MS. 190 
 191 
3.2. Intracellular metabolite extraction from HT-29 cells 192 
The issue of normalization is still unresolved in cell metabolomics. The changes in metabolite 193 
concentrations can greatly vary because of the effect of the treatment on the cell proliferation and hence, 194 
in the number of cells. To overcome this limitation, in the present work, cell normalization was 195 
accomplished counting cells. To undertake this, a distinction has to be made between cells grown in 196 
suspension and adherent cells. Adherent mammalian cells, as the ones used in this work, entail additional 197 
methodological difficulties, compared to those in suspension, since cell detachment has to be carried out 198 
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as a prerequisite prior to cell counting. Although some sample preparation procedures focused on 199 
metabolomics have been described for mammalian adherent cells [37], comparative studies are rare, and 200 
thus, currently there is not a validated and standardized procedure for this purpose [15]. Therefore, for all 201 
metabolite extractions carried out in this work, HT-29 cells were first harvested, subsequently detached, 202 
and finally counted. We selected 10 million cells for metabolite extraction as a good compromise between 203 
sensitivity, size and ease of handling of cell culture. Namely, after a washing step with cold isotonic PBS, 204 
detached cells were counted and sample volumes containing 10 million cells were subjected to metabolite 205 
extraction. After obtaining the selected number of cells, a mechanical procedure to disrupt cells and 206 
release metabolites was applied. Three cycles of freezing/thawing and homogenization, were used for this 207 
purpose [19,38]. A scheme of the experimental procedure for intracellular metabolite extraction from 208 
adherent HT-29 cells can be seen in Fig. 2. Given the variety of extraction solvents available, the choice 209 
of the most suitable one is not an easy task, as it is expected that different solvents will bring the 210 
extraction of different classes of metabolites based on their different polarity. It is expected that aqueous 211 
solutions will result in poor extraction of hydrophobic compounds, whereas organic solvents provide 212 
higher efficiency extraction for non-polar metabolites. Based on our own experience [39] and literature 213 
[40-44], four different extraction solvents were tested in this work, namely, water (W), water-formic acid 214 
(95:5, v/v) (AW), acetonitrile (ACN) and isopropyl alcohol-acetonitrile-water (3:3:1, v/v/v) (IAW). Thus, 215 
the efficiency of each solvent for extracting intracellular metabolites from HT-29 was firstly studied on 216 
cultured HT-29 cells incubated with complete medium for 48 h using a non-targeted metabolomic 217 
approach. Special focus was next put on the study of metabolites related to the polyamines pathway, since 218 
polyamine metabolism has been described as an attractive target for cancer chemoprevention and 219 
chemotherapy [45]. The compatibility of the extraction solvent with the subsequent CE-TOF MS analysis 220 
was also taken into account, as well as the additional advantage provided by organic solvents regarding 221 
protein precipitation. For comparison purposes, injected sample volume was 12 nL.. When organic 222 
extracts were directly injected unstable current at the beginning of the CE-TOF MS analysis or even 223 
current failure, was observed. Therefore, prior to their injection organic extracts were diluted (1:1, v/v) in 224 
11 
 
CE separation buffer (24 nL were injected in those cases). More specifically, the choice of the extraction 225 
solvent was made according to the best performance in terms of metabolite number and signal intensity, 226 
as well as the reliability and repeatability of the extraction method. Thus, CE-TOF MS metabolic profiles 227 
obtained for each extraction solvent were evaluated using non-targeted approaches by determining 228 
features (unique metabolite signals at a given migration time value). Different algorithms for automatic 229 
low molecular weight compounds detection (m/z signals detection, peak building, peak deconvolution, 230 
etc.) were applied for non-targeted metabolomics. Alignment of metabolic signals among all samples was 231 
then carried out [7]. Only those features with lower variability (median/average values <1.5) and detected 232 
in 80% of extracts obtained with each extraction solvent were considered. MZmine data processing and 233 
the subsequent peak filtering and adduct grouping processes allowed us to detect 105, 87, 61 and 44 234 
metabolites for W, AW, IAW, and ACN, respectively. In Fig. 3 the metabolite coverage overlap is 235 
represented by means of a Venn diagram. As can be deduced from this figure, only 27 out of 145 total 236 
detected metabolites are common to the four extracts indicating a high complementarity in metabolic 237 
information provided by the four solvents. The overall metabolic differences obtained for each extraction 238 
solvent was also studied by PCA (supplementary information, Fig. S1). PC1 clearly separates water 239 
extraction from the other three solvents suggesting metabolic information in water is very different. On 240 
the other hand, PC2 is the responsible of the separation between aqueous from organic extracts. As can be 241 
observed in the PC1 vs. PC2 plot, the two organic-based extracts are the more similar and their 242 
differentiation is explained by PC3 (data not shown). 243 
As mentioned above, special focus was put on metabolites related to the polyamines pathway, because of 244 
their role in cell proliferation and carcinogenesis [46]. Representative extracted ion electropherograms 245 
(EIEs) of 13 polyamine-related metabolites are given in Fig. 4. As can be seen, the peaks were separated 246 
without interferences from other endogenous substances in the samples. Peaks corresponding to 247 
polyamine-related compounds were eluted from 4 to 10 min. These compounds (namely, spermine, 248 
spermidine, putrescine, acetylspermine, ornithine, arginine, S-adenosylmethionine, adenine, 249 
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acetylputrescine, S-adenosyl-L-homocysteine, methionine, adenosine, and 5’-deoxy-5’-250 
(methylthio)adenosine) belong to the polyamine pathway (vide infra). As indicated above, five injections 251 
were carried out for each extraction solvent, and thus, % RSD values of peak areas for the 13 polyamine-252 
related metabolites were calculated for each solvent, the results are given in Table 1. Marked differences 253 
in terms of the selectivity of metabolite extraction were observed among the four extraction solvents. AW 254 
(Fig. 4A) and W (Fig. 4B) solvents gave the best overall performance in terms of intensity, number of 255 
extracted metabolites and repeatability. Only three polyamines-related metabolites were found in higher 256 
concentration in the organic-based extracts: acetylspermine and adenosine in ACN extract (Fig. 4C), and 257 
5'-Deoxy-5'-(methylthio)adenosine in the IAW extract (Fig. 4D), showing in both cases (ACN and IAW) 258 
much higher relative standard deviation values (RSD): 9-88%. When W and AW were compared 259 
important differences were also found. Spermine and spermidine, as well as adenosine and S-260 
adenosylmethionine were found in higher quantity in the AW extract. Spermine, spermidine, adenosine 261 
and S-adenosylmethionine were also found in the W extract, although peak intensities were lower. On the 262 
contrary, arginine, adenine, S-adenosyl-L-homocysteine, methionine, and 5’-deoxy-5’-263 
(methylthio)adenosine, were found in higher quantity in the W extract. Unfortunately, putrescine and 264 
ornithine, were not detected using any of the four selected extraction solvents and analysis conditions. 265 
Moreover, it was also observed that the best repeatability values for metabolites extraction were obtained 266 
using W with %RSD ranging from 6 to 9 % (see Table 1). 267 
In order to evaluate the extraction protocol in more detail, additional evaluation of the data using principal 268 
component analysis (PCA) was performed (supplementary information, Fig. S2). PC1, which explains the 269 
most of the data total variance (45%), revealed that W was the most different solvent among the four 270 
extraction solvents. Arginine, adenine, S-adenosyl-L-homocysteine, methionine are directly correlated 271 
with PC1, and as mentioned before, they were found at higher levels in W extract. PC2 explains 31% of 272 
the total variance of the data and segregates AW extract from the other three solvents. PC2 is directly 273 
correlated with adenosine indicating higher levels of that metabolite in IAW, ACN and W solvents. 274 
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However, PC2 inversely correlates with spermine, spermidine and S-adenosylmethionine that are found at 275 
higher concentrations in the AW extract. Overall, extraction with W provided better repeatability and 276 
higher number of small-size compounds were detected when a non-targeted analysis was carried out and, 277 
therefore, water was selected as extraction solvent for the following experiments. 278 
 279 
3.3. Evaluation of intracellular metabolic extraction: Effect of DFMO on HT-29 proliferation 280 
In order to evaluate both the antiproliferative effect of DFMO on colon cancer cells and the usefulness of 281 
the proposed methodology, HT-29 cells were incubated with 4.6 mM of DFMO for 24, 48 and 72 h and 282 
cell proliferation compared to the non-treated HT-29 cells (control) was analyzed by the MTT assay. 283 
After 24 h, no statistically significant differences were observed between the viability of control and 284 
treated cells. However, a reduction of ~20% of the cell proliferation was observed at 48 h (p-value = 285 
0.002), while DFMO exhibited its maximum antiproliferative effect at 72 h, decreasing the cell viability 286 
in ~40% (p-value = 0.0002). DFMO is an inhibitor that blocks the action of ornithine decarboxylase 287 
(ODC) [47], an enzyme that produces the decarboxylation of ornithine into putrescine, which is the first 288 
step of polyamine biosynthesis (see Fig. 5). Polyamine biosynthesis has been shown to be necessary for 289 
cell proliferation, and plays a crucial role in rapidly dividing cells such as cancerous cells [48,49]. 290 
Using the extraction protocol described above (see Fig. 2) and water as extraction solvent, larger sample 291 
volumes could be injected in the CE capillary without compromising the CE current stability. Therefore, 292 
up to 60 nL could be injected in the CE-MS system. This brought an increase of sensitivity, and 13 293 
polyamine-related metabolites could be detected, namely, spermine, spermidine, putrescine, 294 
acetylspermine, ornithine, arginine, S-adenosylmethionine (SAM), adenine, acetylputrescine, S-adenosyl-295 
L-homocysteine (SAH), methionine, adenosine, and 5’-deoxy-5’-(methylthio)adenosine (MTA). 296 
Compounds related to the polyamine pathway mapping were first studied comparing the HT-29 cells 297 
treated for 48h vs. control cells. Significant depletion of spermidine and spermine as well as putrescine, 298 
acetylspermine and 5’-deoxy-5’-(methylthio)adenosine was observed after DFMO cell treatment. 299 
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Spermidine is derived from putrescine by addition of an aminopropyl group via spermidine synthase, and 300 
spermine is derived from spermidine by addition of another aminopropyl group catalyzed by spermine 301 
synthase. According to that, the observed putrescine and spermidine depletion was in good agreement 302 
with the expected activity of DFMO. Moreover, ornithine, which could not be detected under the 303 
analytical conditions described in the previous section “Intracellular metabolite extraction from HT-29 304 
cells”, was detected in a greater amount in DFMO-treated cells when higher amount of sample was 305 
injected. These results are also consistent with the selective blockade of the ODC enzyme by DFMO. 306 
Interestingly, MTA levels decreased significantly in DFMO-treated cells relative to control cells. Recent 307 
evidences suggest a key role for methionine cycle intermediates, including SAM, SAH and MTA, in the 308 
cytostatic activity of DFMO [50]. More specifically, DFMO treatment reduces methionine cycle 309 
metabolism in normal human colon epithelial cells and colorectal cancer cells as well, which has been 310 
associated with decreases in one-carbon-dependent thymidine metabolite pools. Other polyamine-related 311 
metabolites indicated in Fig. 5 were detected but not significantly altered with the DFMO treatment. 312 
A non-targeted metabolomic approach was also carried out with the aim to gain insight into other 313 
metabolic pathways that could be altered upon DFMO treatment. In order to extract the most significant 314 
differences between treated HT-29 cells with respect to the control cells, 70 detected metabolite 315 
compounds were aligned and subjected to statistical analysis. Among the 10 significantly different 316 
metabolites detected applying an ANOVA (p-value set at 0.05), cysteinyl-glycine was assigned by 317 
matching the experimental mass spectra with information contained in HMDB, METLIN and KEGG 318 
databases. Eight out of ten metabolites significantly altered were first tentatively identified by using 319 
metabolite databases and they were next confirmed by standard co-injection, while only one metabolite 320 
(170.067 m/z migrating at 7.1 min) remained unknown. Fig. 6 summarizes the 10 compounds that 321 
changed significantly (p-value <0.05) after the DFMO treatment detected by a non-target metabolomics 322 
approach. As can be seen in Fig. 6, the levels of three metabolites increased whereas seven metabolites 323 
decreased their concentration in DFMO-treated HT-29 cells. Interestingly, following a non-targeted 324 
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metabolomic approach, the polyamines pathway also came out as the main route altered by DFMO as can 325 
be deduced from the 5 metabolites related to the mentioned polyamines synthesis (namely, putrescine, 326 
ornithine, MTA, N-acetylputrescine, and spermidine) corroborating the usefulness of this approach. The 327 
non-targeted metabolomic analysis also suggested that DFMO treatment induces changes in several 328 
compounds related with glutathione metabolism, including GSH, GSSG and cyteinyl-glycine. More 329 
precisely, increases in intracellular GSH and cysteinyl-glycine contents were concomitant with a decrease 330 
in GSSG levels in treated cells. Glutathione-related metabolites participate in antioxidant defense and 331 
many other metabolic processes [51,52]. The elevation of intracellular GSH in DFMO-treated cells was in 332 
good agreement with reported data in literature [53-56]. Hunter et al. observed that elevation of GSH 333 
concentration induced by 1 mM DFMO in rat brain tumor cells was the result of increased GSH synthesis 334 
[53]. Polyamines have a recognized reactive oxygen species scavenger function [54,55]. Thus, the 335 
observed changes in GSH levels can be explained as the cellular response to altered ROS levels occurring 336 
upon intracellular polyamine depletion induced by DFMO-treatment. As mentioned before, the dipeptide 337 
cysteinyl-glycine, the GSH catabolite generated by gamma-glutamyltranspeptidase, significantly 338 
increased in DFMO-treated cells. Cysteinyl-glycine has been suggested to participate in GSH 339 
homeostasis, controlling GSH synthesis, and therefore, affecting the antioxidant defense of the cell [56].  340 
In addition, decreased levels of gamma-aminobutyric acid (GABA) in DFMO-treated cells compared to 341 
control cells, were observed. GABA accumulation in several tumor processes [57-59] including colorectal 342 
cancer [60] has been well documented. Specifically, diamine oxidase is responsible for GABA generation 343 
from putrescine, and increased levels of this enzyme have been associated with higher malignancy 344 
probability in cancer progress [58]. Furthermore, there is certain feedback between GABA levels and 345 
polyamine biosynthesis since the former metabolite stimulates ODC activity [61,62]. Thus, increased 346 
GABA levels induce ODC activity resulting in higher putrescine levels, which is in turn a precursor of 347 
GABA. 348 
 349 
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4. CONCLUSIONS 350 
An effective protocol for metabolomics of adherent mammalian cells has been developed in this work. 351 
The protocol allows intracellular metabolite extraction and normalization prior to metabolomic analysis, 352 
making possible a quantitative comparison of cell metabolomic profiles. Our method comprises a reliable 353 
sample preparation step to extract metabolites with especial emphasis on polyamine related metabolites 354 
from HT-29 cell line. Although acidified water gave best extraction yields for spermine, spermidine, 355 
adenosine and S-adenosylmethionine, extraction with water gave better yields for arginine, adenine, S-356 
adenosyl-L-homocysteine, methionine, and 5’-deoxy-5’-(methylthio)adenosine. Furthermore, this last 357 
polyamine compound was not detected in acidified water extract. The selection of water as the optimum 358 
extraction solvent for polyamines profiling led to an increase in CE-TOF MS sensitivity by means of a 359 
higher sample volume injection, by which putrescine and ornithine could be detected. These two 360 
compounds together with 8 more metabolites, namely gamma-aminobutyric acid (GABA), oxidized and 361 
reduced glutathione, 5’-deoxy-5’-(methylthio)adenosine, N-acetylputrescine, cysteinyl-glycine, 362 
spermidine and an unknown compound were found to be significantly altered (p<0.05) by DFMO 363 
following a non-targeted metabolomics approach. This finding indicates that DFMO treatment especially 364 
affects the polyamine metabolism, and other relevant metabolic pathways (e.g., related to intracellular 365 
thiol redox state) as well. The results from DFMO treated and control cells corroborate the usefulness of 366 
the whole method for intracellular cell metabolomics. Besides, the protocol showed to be robust and 367 
reliable for intracellular metabolic profiling of HT-29 cells. CE-TOF MS is particularly suited for the 368 
rapid separation of ionic, weakly ionic, and/or highly polar metabolites with very high resolution using 369 
minimal volumes of reagents and sample. Taking into account this last point, further improvements on 370 
sample preparation using less quantity of cells and less extraction solvents are therefore affordable 371 
without analytical limitations. However, when using one single analytical technique for a particular 372 
metabolomic study it has to be assumed that a significant bias is introduced into the final results. It would 373 
be therefore important to point out that in order to provide more global metabolomic information, a 374 
17 
 
combination of NMR, GC/MS, LC/MS and CE/MS for metabolomics analysis should be ideally 375 
employed. 376 
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FIGURE CAPTIONS 540 
 541 
Figure 1. CE-TOF MS base peak electropherogram (BPE) and extracted ion electropherograms (EIE) of 542 
the QC mixture containing 19 polyamine related compounds: 1: spermine; 2: spermidine; 3: putrescine; 4: 543 
cadaverine; 5: N-acetylspermine; 6: ornithine; 7: lysine; 8: arginine; 9: S-adenosylmethionine; 10: 544 
adenine; 11: N-acetylputrescine; 12: S-adenosyl-L-homocysteine, 13: N-Acetylornithine; 14: cytidine; 15: 545 
methionine; 16: adenosine; 17: 5’-deoxy-5’-(methylthio)adenosine; 18: oxidized glutathione; 19: reduced 546 
glutathione (0.1 mM each). Metabolites were separated in a bare fused silica capillary with 80 cm total 547 
(and effective) length and 50 μm i.d., filled with 3 M formic acid as BGE; running voltage was +27 kV 548 
and temperature 25ºC. Injection was made at the anodic end using N2 pressure of 0.5 psi for 16 s (12 nL). 549 
Figure 2. Experimental flowchart for intracellular metabolite extraction from HT-29 colon cancer cells. 550 
Figure 3. Venn diagram representation of number of HT-29 intracellular metabolites extracted with 551 
acidized water (AW), water (W), acetonitrile (ACN) and isopropyl alcohol-acetonitrile-water (IAW) 552 
following a non-targeted metabolomic approach. 553 
Figure 4. Representative extracted ion electropherograms of the 13 polyamine-related metabolites from 554 
extracts obtained with (A) acidized water, (B) water, (C) acetonitrile, and (D) isopropyl alcohol-555 
acetonitrile-water. From top to bottom: Spermine, spermidine, putrescine, acetylspermine, ornithine, 556 
arginine, S-adenosylmethionine, adenine, acetylputrescine, S-adenosyl-L-homocysteine, methionine, 557 
adenosine, 5'-deoxy-5'-(methylthio)adenosine. Injections were made at the anodic end using N2 pressure 558 
of 0.5 psi for 16 s (12 nL) for acidized water and water extracts and for 32 s (24 nL) for acetonitrile and 559 
isopropyl alcohol-acetonitrile-water extracts (previously diluted 1:1 (v/v) with BGE). Rest separation 560 
conditions as in Fig. 1. 561 
Figure 5. Polyamine pathway mapping. Oval shape nodes represent genes and rectangular nodes 562 
represent metabolites. 563 
Figure 6. Whisker plot representing the mean values (±SD) of the metabolites showing significant 564 
differences (p<0.05) after DFMO treatment of the HT-29 colon cancer cells. 565 
  566 
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Table 1. Variability of metabolite extraction (five extractions for each condition): Water (W), acidified water 567 
(AW), acetonitrile (ACN) and isopropyl alcoholacetonitrile-water (IAW). 568 
  Metabolite database  % RSD peak area (n=5) 
Compound 
Molecular 
formula 
METLIN KEGG HMDB m/z [M+H]
+
 W AW ACN IAW 
Spermine C10H26N4 255  C00750  HMDB01256  203.2230 6 6 ND 54 
Spermidine C7H19N3 254  C00315  HMDB01257  146.1652 9 6 29 41 
Putrescine C4H12N2 3226  C00134  HMDB01414  89.1073 ND ND ND ND 
Acetylspermine C12H28N4O 3369  C02567  HMDB01186  245.2336 ND ND 88 ND 
Ornithine C5H12N2O2 27 C01602  HMDB00214  133.0972 ND ND ND ND 
Arginine C6H14N4O2 13 C00062  HMDB00517  175.119 6 14 27 10 
S-Adenosylmethionine C15H23N6O5S 3289  C00019  HMDB01185  399.1445 6 6 32 9 
Adenine C5H5N5 85 C00147  HMDB00034  136.0618 9 10 23 23 
Acetylputrescine C6H14N2O 3252  C02714  HMDB02064  131.1179 ND ND ND ND 
S-Adenosyl-L-
homocysteine 
C14H20N6O5S 296  C00021  HMDB00939  223.0747 9 11 51 19 
Methionine C5H11NO2S 26 C00073  HMDB00696  150.0583 8 12 15 9 
Adenosine C10H13N5O4 86 C00212  HMDB00050  268.104 7 13 52 29 
5'-Deoxy-5'-
(methylthio)adenosine 
C11H15N5O3S 3425  C00170  HMDB01173  298.0968 9 ND ND 15 
ND: Not detected                   
 569 
